Investigating the Gut Microbiota Modulation Effects of Allicin for Cardiovascular Disease Protection and Establishing Microbiota Directed Personalized Nutrition Guidance With Novel Humanized Gnotobiotic Mice Model, Microbial Culturomics and Metabolomic Technique
1 other identifier
interventional
9
1 country
1
Brief Summary
Investigators recruited 10 trimethylamine N-oxide (TMAO) producers to test the effect of garlic juice containing allicin on gut microbiota modulation and TMAO production.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Mar 2019
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 18, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 18, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
May 18, 2019
CompletedFirst Submitted
Initial submission to the registry
September 6, 2020
CompletedFirst Posted
Study publicly available on registry
September 11, 2020
CompletedSeptember 16, 2020
February 1, 2019
2 months
September 6, 2020
September 14, 2020
Conditions
Outcome Measures
Primary Outcomes (2)
Plasma and urine TMAO level (ppm)
Quantitation of plasma and urine TMAO level by LC-MS
6 months
Compositional analysis of gut microbiota (% of different bacteria species)
Next-generation sequencing and bioinformatics
6 months
Study Arms (1)
Raw garlic juice
EXPERIMENTALRaw garlic juice treatment group
Interventions
Fresh garlic juice containing around 48mg allicin for 7 days
Eligibility Criteria
You may qualify if:
- Age 20-65 years old
- Healthy subjects with TMAO producing ability
You may not qualify if:
- Exposure to antibiotics, probiotics, or carnitine supplements within the previous month
- Have a history of chronic diseases including, diabetes mellitus, myasthenia gravis, chronic renal disease, hyperparathyroidism, epilepsy, and severe anemia
- Have gastrointestinal discomfort (such as abdominal pain or diarrhea)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
National Taiwan University Hospital
Taipei, 100, Taiwan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ming-Shiang Wu
National Taiwan University Hospital
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 6, 2020
First Posted
September 11, 2020
Study Start
March 18, 2019
Primary Completion
May 18, 2019
Study Completion
May 18, 2019
Last Updated
September 16, 2020
Record last verified: 2019-02